Latest Capricor Therapeutics Inc. (CAPR) Headlines
Post# of 53
Posted On: 03/09/2014 5:41:22 AM
Latest Capricor Therapeutics Inc. (CAPR) Headlines
Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
GlobeNewswire - Mon Jan 06, 7:30AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech, Inc. (Janssen). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002. CAP-1002 is an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction. Pursuant to the agreement, Capricor and Janssen will collaborate on elements of cell manufacturing development. Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of $12.5 million from Janssen.
Capricor Therapeutics Announces Ticker Symbol Change to CAPR
Business Wire - Fri Dec 20, 5:00AM CST
Capricor Therapeutics, Inc. (OTCBB: CAPR), a diversified heart failure biotechnology company, today announced that, effective today, the Company's common stock commences trading on the OTC Markets under the new symbol "CAPR." The previous trading symbol was "NLTXD." The ticker symbol change follows the recently completed merger between Capricor, Inc. and Nile Therapeutics, Inc.
Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
GlobeNewswire - Mon Jan 06, 7:30AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech, Inc. (Janssen). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002. CAP-1002 is an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction. Pursuant to the agreement, Capricor and Janssen will collaborate on elements of cell manufacturing development. Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of $12.5 million from Janssen.
Capricor Therapeutics Announces Ticker Symbol Change to CAPR
Business Wire - Fri Dec 20, 5:00AM CST
Capricor Therapeutics, Inc. (OTCBB: CAPR), a diversified heart failure biotechnology company, today announced that, effective today, the Company's common stock commences trading on the OTC Markets under the new symbol "CAPR." The previous trading symbol was "NLTXD." The ticker symbol change follows the recently completed merger between Capricor, Inc. and Nile Therapeutics, Inc.
(0)
(0)Capricor Therapeutics Inc. (CAPR) Stock Research Links
Scroll down for more posts ▼